For patients with Charcot-Marie-Tooth disease type 2C, a progressive and debilitating neuromuscular disorder, the clinical development path is often a story of dead ends. The genetic condition, caused by specific mutations, has no approved disease-modifying therapies. When Jazz Pharmaceuticals acquired Actio Biosciences for $820 million last year, the deal was centered on a different rare epilepsy program. Left behind was a clinical-stage asset, an oral TRPV4 inhibitor, with a distinct genetic rationale for CMT2C. Now, that compound has become the foundation for a new company, launched with a $90 million Series A to see if genetics can finally chart a course to treatment [BioPharma Dive, October 2026][Fierce Biotech, October 2026].
Setara Biosciences represents a deliberate second act. It is a corporate spinout, formed from the Actio programs not included in the Jazz acquisition and staffed by key Actio alumni. The financing, announced on October 30, 2026, was led by a syndicate of biotech-focused funds including Deerfield Management, Canaan, and Regeneron Ventures, with strategic participation from Jazz itself [Business Wire, October 2026]. For CEO and founder David Goldstein, a renowned human genetics professor at Columbia University, the launch is less about starting over and more about following a precise scientific thread to its logical, and hopeful, conclusion.
A genetics-first pipeline
The company's entire thesis is built on a foundational layer of human genetics. Goldstein's academic and commercial work has long focused on using genetic insights to identify biologically validated targets, a approach meant to de-risk the treacherous path of drug development. Setara's lead asset, now called STAR-0871, is a direct product of that philosophy. It is an oral small-molecule inhibitor of the TRPV4 ion channel, a target implicated in the nerve degeneration seen in CMT2C [Setara Biosciences, retrieved 2026].
The program is not starting from scratch. It had already completed the healthy-volunteer portion of a Phase 1 trial initiated by Actio in March 2025 [Fierce Biotech, October 2026]. Setara's near-term capital is earmarked to advance the drug into a Phase 1b study in CMT2C patients, planned for 2027. The compound also holds FDA designations that underscore both the unmet need and its potential pathway: it has received rare pediatric disease, orphan drug, and fast-track status [Fierce Biotech, October 2026]. While CMT2C is the primary focus, the company is also exploring the drug's utility in overactive bladder, a much larger market that could help subsidize the rare disease work.
The team behind the spinout
The continuity from Actio to Setara is most evident in its leadership, a team that brings deep domain expertise in ion channel biology and translational science. This is not a group of first-time founders navigating the FDA for the first time.
| Role | Name | Prior Affiliation & Notes |
|---|---|---|
| President, Executive Chair & Founder | David Goldstein, Ph.D. | Founder of Actio Biosciences; Professor of Genetics at Columbia University; chaired AstraZeneca’s Genomics Advisory Board [Reuters, April 2016][PERPLEXITY SONAR PRO BRIEF, October 2026]. |
| Chief Scientific Officer | David Breckenridge, Ph.D. | Co-founder and CSO of Actio Biosciences; continues in the same role at Setara [PERPLEXITY SONAR PRO BRIEF, October 2026]. |
| Chief Financial Officer | Cayce Denton | Former Actio Biosciences finance executive [PERPLEXITY SONAR PRO BRIEF, October 2026]. |
Goldstein's academic pedigree provides a tangible link to the foundational science. His role leading Columbia's Institute for Genomic Medicine and his advisory work with large pharma give Setara a credibility that resonates with both investors and potential future partners [Columbia University Irving Medical Center, retrieved 2026]. The team's collective experience shepherding Actio's lead program to a successful acquisition by Jazz is perhaps the most relevant proof point for their ability to execute this next chapter.
The investor vote of confidence
A $90 million Series A for a newly formed entity is a substantial declaration of faith, particularly in a biotech funding environment that can be cautious. The investor list reads like a who's who of sophisticated life science capital.
- Deerfield Management & Canaan: Experienced healthcare investors with long histories of backing novel therapeutic platforms.
- Droia Ventures, EcoR1, Euclidean Capital: Niche biotech VFs known for deep technical diligence.
- Regeneron Ventures: The corporate venture arm of Regeneron, a company built on genetic medicine.
- Jazz Pharmaceuticals: The strategic acquirer of Actio, now a shareholder in the spinout, creating an aligned interest in Setara's success [Business Wire, October 2026].
The round's size suggests investors are funding not just the Phase 1b study for STAR-0871, but also the earlier-stage pipeline the company plans in other rare diseases, epilepsy, and migraine [PERPLEXITY SONAR PRO BRIEF, October 2026]. It is capital designed to reach multiple clinical inflection points, reducing the need for a near-term follow-on round.
Navigating a high-stakes development path
The risks here are not hidden. They are the intrinsic challenges of developing a drug for a severe, progressive rare disease. The patient population for CMT2C is small and geographically dispersed, making clinical trial recruitment a complex and lengthy endeavor. While the genetic rationale and preclinical data are compelling, the Phase 1b study in patients will be the first true test of whether inhibiting TRPV4 can alter the course of the disease. Furthermore, the path to regulatory approval and reimbursement for a potential high-cost therapy in a rare disease is never straightforward.
Setara's most plausible answer to these risks is embedded in its model. The genetics-driven target selection is meant to increase the odds of clinical success. The strategic backing from Jazz provides a layer of stability and industry insight. And the $90 million war chest is intended to give the team the runway to generate clean, interpretable clinical data that can either support advancement or provide a clear stopping point.
For the several thousand patients worldwide living with CMT2C, the standard of care today is primarily supportive. It involves physical therapy, orthopedic devices like braces, and pain management to address symptoms like muscle weakness, foot deformities, and loss of sensation. There is no treatment to slow or halt the underlying neurodegeneration. This is the patient population Setara is aiming to serve, and the profound unmet need is what makes the high-risk, high-reward calculus of drug development in this space worth attempting. The next twelve months will be about operational execution: finalizing the clinical trial design, activating sites, and enrolling the first patients into the Phase 1b study. For Pulse Raman, the story is less about the $90 million and more about the families waiting to see if this genetic clue finally leads somewhere.
Sources
- [Business Wire, October 2026] Setara Biosciences Announces $90 Million Series A Financing to Advance Precision Medicines for Rare Genetic Diseases and Related Expansion Indications | https://www.businesswire.com/news/home/20261030022827/en/
- [BioPharma Dive, October 2026] With Setara, the team behind Actio opens its second act | https://www.biopharmadive.com/news/setara-actio-charcot-marie-tooth-ion-channel-drugs/873227/
- [Fierce Biotech, October 2026] Jazz’s Actio buyout gives rise to Setara with $90M series A | https://www.fiercebiotech.com/biotech/setara-raises-90m-series-carrying-actio-torch-following-jazz-acquisition
- [PERPLEXITY SONAR PRO BRIEF, October 2026] Company, product, and team details | Sourced from web-grounded research
- [Setara Biosciences, retrieved 2026] Company description and lead product | Sourced from company materials
- [Reuters, April 2016] AstraZeneca taps gene pioneer Venter for huge drug-hunting sweep | https://www.reuters.com/article/us-astrazeneca-genomics-idUSKCN0XI2Z1
- [Columbia University Irving Medical Center, retrieved 2026] David Goldstein faculty profile | Sourced from university website